The Power of Single‐Cell Analysis for the Study of Liver Pathobiology

Angela L. Chu, Joel D. Schilling, Kevin R. King, Ariel E. Feldstein – 1 August 2020 – Single cell transcriptomics has emerged as a powerful lens through which to study the molecular diversity of complex tissues such as the liver, during health and disease, both in animal models and in humans. The earliest gene expression methods measured bulk tissue RNA, but the results were often confusing because they derived from the combined transcriptomes of many different cell types in unknown proportions.

A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Hannah P. Kim, Sarah R. Lieber, Michael E. Rogers, Andrew M. Moon, Marci Loiselle, Jennifer Walker, David N. Assis, Ricky Safer, Rachel Gomel, Donna M. Evon – 1 August 2020 – Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are associated with decreased health‐related quality of life and debilitating symptoms. These experiences can be defined as patient‐reported outcome (PRO) concepts and measured using PRO instruments. We identified all PRO concepts and instruments used in the PBC and PSC literature.

Managing Recipient Hepatic Artery Intimal Dissection During Living Donor Liver Transplantation

Shaleen Agarwal, Rajesh Dey, Yuktansh Pandey, Sapana Verma, Subash Gupta – 31 July 2020 – Recipient hepatic artery intimal dissection (HAD) followed by hepatic artery thrombosis (HAT) is a serious complication of liver transplantation. Once this is recognized intraoperatively, the accepted approach is to use an alternative arterial inflow, which may not be possible in all patients. We describe a new classification and technique for the management of HAD during living donor liver transplantation. On the basis of the longitudinal extent of intimal dissection, HAD was classified into 4 types.

Center Variation in Intention‐to‐Treat Survival Among Patients Listed for Liver Transplant

Allison J. Kwong, Avegail Flores, Giovanna Saracino, Jodi Boutté, Greg McKenna, Giuliano Testa, Ranjeeta Bahirwani, Anji Wall, W. Ray Kim, Göran Klintmalm, James F. Trotter, Sumeet K. Asrani – 29 July 2020 – In the United States, centers performing liver transplant (LT) are primarily evaluated by patient survival within 1 year after LT, but tight clustering of outcomes allows only a narrow window for evaluation of center variation for quality improvement. Alternate measures more relevant to patients and the transplant community are needed.

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice

Anja Christina Koop, Nina Doreen Thiele, David Steins, Erik Michaëlsson, Malte Wehmeyer, Ludger Scheja, Babett Steglich, Samuel Huber, Julian Schulze zur Wiesch, Ansgar W. Lohse, Jörg Heeren, Johannes Kluwe – 29 July 2020 – Myeloperoxidase (MPO) activity has been associated with the metabolic syndrome, cardiovascular and liver disease. Here, we evaluate the therapeutic potential of MPO inhibition on nonalcoholic steatohepatitis (NASH) and NASH‐induced fibrosis, the main determinant of outcomes.

Subscribe to